AFFILIATIONS
1 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
2 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
3 Worldwide Clinical Trials, San Antonio, Texas, United States
4 Daiichi Sankyo Co., Ltd, Tokyo, Japan
5 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
6 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
7 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
8 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
9 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
10 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
11 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
12 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
13 Clario, Philadelphia, Pennsylvania, United States
14 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
15 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
ABSTRACT
Background
Quizartinib is an oral, highly potent, and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor approved for treatment of newly diagnosed FLT3-internal tandem duplication (ITD)–positive acute myeloid leukemia. In the pivotal QuANTUM-First trial, quizartinib in combination with standard induction and consolidation chemotherapy, and as maintenance monotherapy, provided an overall survival benefit compared with placebo (median 31.9 vs 15.1 mo, respectively). Quizartinib prolongs the QT interval by inhibiting the slow delayed rectifier potassium current (IKs). In contrast to more common inhibitors of the rapid delayed rectifier potassium current (IKr; commonly known as hERG), the clinical consequences of IKs inhibition are less well characterized. Pharmacologic IKs blockade may theoretically mimic congenital long QT syndrome type 1 (LQTS1), which is caused by loss-of-function mutations in IKs and is characterized by impaired QT shortening during increased heart rate (HR). As part of the US Food and Drug Administration approval of quizartinib in 2023, a postmarketing requirement was issued to evaluate the impact of rapid acceleration in HR on the cardiac safety of quizartinib using a graded-intensity bicycle exercise test in healthy participants and to report the incidence of arrhythmias and other adverse reactions. This study was designed to test the hypothesis that quizartinib treatment may result in delayed or blunted QT interval shortening during periods of increased HR. Central to this study is the assessment of the effect of rapid HR acceleration on corrected QT interval (QTc) prolongation and cardiac repolarization to determine whether IKs inhibition with quizartinib displays impaired QTc shortening under exercise, as is seen in patients with LQTS1 (Acta Cardiol Sin 2022;38:124–133).
Methods
AC220-165 was a phase 1, single-blind, fixed-sequence study in healthy adult participants who received single oral doses of placebo (Day 1) and quizartinib 90 mg (Day 2). Participants underwent a graded bicycle exercise and postural provocation after both treatments to induce rapid HR acceleration. Electrocardiograms (ECGs) were continually monitored using Holter monitors, and triplicate ECGs were collected at baseline, during rapid HR accelerations, and during recovery. QT analyses using Fridericia (QTcF) and individually (QTcI) corrected QT intervals were conducted. Plasma concentrations of quizartinib and its major metabolite, AC886, were assessed.
Results
In total, 73 participants were enrolled and 70 participants completed the study. The median (range) age was 35 (18–54) years, and most participants were male (64.4%) and White (64.4%). At the median Tmax (time to quizartinib maximum plasma concentration [Cmax]) and before exercise, the mean placebo-adjusted change in QTcF (ΔΔQTcF) and QTcI (ΔΔQTcI) were 16.1 and 15.8 ms, respectively, consistent with the magnitude of QTc prolongation in the QuANTUM-First study (ΔΔQTcF of 18 ms and 24 ms at steady state Cmax of 30 mg and 60 mg quizartinib, respectively). Exercise increased HR, with mean changes from baseline (ΔHR) at peak exercise of 75.3 bpm on Day 1 (placebo) and 76.6 bpm on Day 2 (quizartinib). Appropriate QTc shortening was observed during both postural provocation and graded bicycle exercise on the placebo and quizartinib treatment days. Quizartinib-induced QT prolongation was not exacerbated at peak exercise, with mean ΔΔQTcF and ΔΔQTcI values of 9.9 ms (90% confidence interval [CI], 6.17–13.60) and 10.1 ms (90% CI, 6.83–13.32), respectively, compared with corresponding pre-exercise values of 16.1 ms and 15.8 ms. A QTc-HR bin analysis demonstrated preserved QTc shortening across HR bins up to 150 bpm. RR, PR, and QRS intervals and ECG morphology remained unchanged on quizartinib treatment. No arrhythmias or serious adverse events were observed.
Conclusion
Preserved QTc shortening during exercise indicates an intact repolarization reserve at therapeutic exposure of quizartinib, suggesting demonstrating that quizartinib treatment does not recapitulate the pathologic phenotype of LQTS1 due to IKs dysfunction. Instead, the QT prolongation profile of quizartinib is consistent with that of conventional IKr/hERG blocking agents, supporting the adequacy of standard QTc-based ECG monitoring for patients receiving quizartinib.
DISCLOSURES
Yuan Xu: Daiichi Sankyo - Current equity holder in publicly-traded company; Daiichi Sankyo - Current Employment